| Graceway Counseling Center | |
|
744 4th Ave Ste 2 Huntington WV 25701-1541 | |
| (304) 691-0873 | |
| (304) 955-9057 |
| Full Name | Graceway Counseling Center |
|---|---|
| Speciality | Nurse Practitioner |
| Location | 744 4th Ave Ste 2, Huntington, West Virginia |
| Authorized Official Name and Position | Matthew Maynard (OWNER) |
| Authorized Official Contact | 3046910873 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Graceway Counseling Center 33 Walnut Ln Huntington WV 25704-9485 Ph: (304) 638-1551 | Graceway Counseling Center 744 4th Ave Ste 2 Huntington WV 25701-1541 Ph: (304) 691-0873 |
| NPI Number | 1003405978 |
|---|---|
| Provider Enumeration Date | 01/14/2021 |
| Last Update Date | 02/26/2024 |
| Certification Date | 02/26/2024 |
| Medicare PECOS PAC ID | 2264894963 |
|---|---|
| Medicare Enrollment ID | O20230811002420 |
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003405978 | NPI | - | NPPES |
| Provider Name | Rebeka A Copley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376090050 PECOS PAC ID: 4486922317 Enrollment ID: I20170619002048 |
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
| Provider Name | Thomas Lester |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1962809293 PECOS PAC ID: 9537504584 Enrollment ID: I20240229000571 |
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
| Provider Name | Jacqueline Rollyson |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1275292054 PECOS PAC ID: 6800231861 Enrollment ID: I20240229000938 |
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
| Provider Name | Matthew Maynard |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1750970711 PECOS PAC ID: 4486638244 Enrollment ID: I20240306001335 |
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
News Archive
The World Health Organization (WHO) today launched a new comprehensive analysis of global health trends since 2000 and an assessment of the challenges for the next 15 years.
Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.
› Verified 1 days ago
Patchwork Therapy And Growth Center, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4766 Us Route 60 Unit B, Huntington, WV 25705 Phone: 304-802-4769 Fax: 304-318-7183 | |
Prestera Center For Mental Health Services, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3375 Us Route 60, Huntington, WV 25705 Phone: 304-525-7851 Fax: 304-697-1286 | |
Cabell Huntington Hospital Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1340 Hal Greer Blvd, Neuro Physiology Lab, Huntington, WV 25701 Phone: 304-526-6387 Fax: 304-526-6327 | |
Hbh Primary Care And Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1415 6th Ave, Huntington, WV 25701 Phone: 304-523-1142 | |
Starlight Behavioral Health Services Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5315 Cherry Lawn Rd, Huntington, WV 25705 Phone: 304-302-2078 Fax: 304-302-0279 | |
Starlight Behavioral Health Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: 304-302-2078 Fax: 304-302-7260 |